bioAffinity Technologies (BIAFW) Current Assets (2021 - 2026)

bioAffinity Technologies has disclosed Current Assets across 6 years of filings, most recently posting $4.3 million for Q1 2026.

• In Q1 2026, Current Assets rose 132.94% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 132.94% YoY), while the FY2025 annual figure was $7.6 million, up 180.7% from the prior year.
• Current Assets slipped to $4.3 million in Q1 2026, from $7.6 million in the prior quarter.
• Over the last five years, Current Assets for BIAFW reached as high as $14.1 million in Q3 2022 and fell as low as $1.7 million in Q2 2025.
• The 5-year median for Current Assets is $4.3 million (2026), against an average of $6.1 million.
• Annual changes were most pronounced in 2022 — Current Assets surged 731.69% — and 2024, when it tumbled 69.05%.
• A 5-year view of Current Assets shows it stood at $12.0 million in 2022, then sank by 66.79% to $4.0 million in 2023, then tumbled by 32.16% to $2.7 million in 2024, then jumped by 180.7% to $7.6 million in 2025, then sank by 42.61% to $4.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $4.3 million, $7.6 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.